Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA accepts NDA for dry eye treatment
➤ Phase 2 study moves forward for investigational ocular autoimmune therapy
➤ Fast-track designation granted for investigational retinitis pigmentosa treatment
➤ First-in-human feasibility study data from drug-eluting IOL platform
➤ Study identifies the ‘best approach’ for anti-VEGF therapy for diabetic retinopathy
➤ ASCRS news and events
➤ FDA approves treatment for subfoveal choroidal neovascularization due to AMD
➤ IND for inherited RPE clinical trial receives FDA clearance
➤ Phase 3 clinical trial to evaluate cooling device for anesthesia prior to injections
➤ Study calls ‘long-believed theory about diabetic cataracts into question’
➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis
➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis
➤ FDA approves IND for research to move forward on RP gene therapy
➤ Phase 2 study to treat geographic atrophy begins
➤ Study: Weaning patients off of AMD treatments compared
➤ Possible geographic atrophy treatment explored
➤ ASCRS news and events
➤ Topline results from Phase 3 study of atropine for myopia progression
➤ Phase 3 results for novel glaucoma drop
➤ Positive results from two Phase 3 studies for patients with RVO
➤ Phase 3 results for cell therapy treating macular telangiectasia type 2
➤ Single injection of investigational compound for DME improves BCVA
➤ FDA accepts BLA for ophthalmic bevacizumab
➤ Mobile phone attachment developed for ophthalmic clinical trials
➤ ASCRS news and events
➤ NDA submitted to FDA for once-daily glaucoma drop
➤ Positive Phase 3 data for novel preservative-free latanoprost delivery method
➤ Phase 4 DME safety study reduces need for treatments
➤ New data from Phase 3 trial for investigational Acanthamoeba keratitis treatment
➤ New findings on visual potential for adults with Leber congenital amaurosis
➤ ASCRS news and events
➤ Positive topline data for travoprost implant
➤ Enrollment complete for dry AMD interventional trial
➤ European Commission approves new treatment for wet AMD and DME
➤ Interim results for first-in-human trial with new glaucoma implant
➤ Three non-antibiotic drugs identified to treat ocular infection
➤ ASCRS news and events
➤ ‘Visionary Report’ sheds light on understanding, perspectives of AMD
➤ NDA submitted for Demodex blepharitis treatment
➤ Study complete for trial of oral diabetic retinopathy therapy
➤ Enrollment complete for study comparing dry eye therapeutic device to cyclosporine
➤ Gene therapy developed for ciliopathy associated with a form of Leber congenital amaurosis
➤ ASCRS news and events
EyeWorld spoke to two physicians for a primer on interpreting OCT of the macula and optic nerve in preparation for cataract surgery.
➤ Two-year results from Phase 3 study for GA therapy
➤ BLA resubmission for bevacizumab
➤ Strategic licensing for pharmacologic treatment for keratoconus
➤ Study: Gene therapy restores some cone function to otherwise colorblind children
➤ ASCRS news and events
➤ 12-month Phase 1 trial data from sustained drug delivery option for anti-VEGF therapy
➤ Phase 1b results for possible topical treatment of corneal injuries
➤ Long-term safety and efficacy reinforced with 2-year clinical trial data of AMD therapy
➤ FDA accepts NDA for GA therapy
➤ NDA submitted for investigational dry eye treatment
➤ Company completes guidance meeting with FDA for dry eye drug
➤ Companies partner to conduct Phase 3 trials for possible NK treatment
➤ Partnership to develop gene therapy
➤ ASCRS news and events
